Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Torvutatug Samrotecan · AZD-5335

Antibody-drug conjugate · Cytotoxic, directed at folate receptor alpha (FOLR1) · developed by ASTRAZENECA

Phase 1 Most advanced trial

AZN Developer

1 Registered trials

What is Torvutatug Samrotecan?

Torvutatug samrotecan is an antibody-drug conjugate composed of a monoclonal antibody targeting folate receptor alpha conjugated to exatecan, a topoisomerase I inhibitor. The antibody binds FRa on tumor cells, enabling cellular uptake and release of exatecan, which inhibits DNA topoisomerase I and induces apoptosis. It is studied in ovarian, fallopian tube, and primary peritoneal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AZD-5335, AZ14170132
Drug type: Antibody-drug conjugate
Targets: folate receptor alpha (FOLR1), DNA topoisomerase I (TOP1) (secondary target)
Mechanism: Cytotoxic, directed at folate receptor alpha (FOLR1)
Pathways: DNA replication inhibition, apoptosis
Therapy area: Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: E5QZ8ZF3HE

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07402915	Phase 1	Fallopian Tube Cancer	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube CancerOvarian CancerPrimary Peritoneal

Other drugs acting on FOLR1

ABBV-901 Phase 1 Opugotamig Olatansine Phase 2 Sofetabart Mipitecan Phase 3 ZW191 Phase 1

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Torvutatug Samrotecan

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z